Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate.
Sonmez, Mehmet
Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate. [electronic resource] - Hematology (Amsterdam, Netherlands) Aug 2009 - 220-3 p. digital
Publication Type: Journal Article
1607-8454
10.1179/102453309X426245 doi
Adaptor Proteins, Signal Transducing
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--therapeutic use
Benzamides
DNA-Binding Proteins--biosynthesis
Female
Humans
Imatinib Mesylate
LIM Domain Proteins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Male
Metalloproteins--biosynthesis
Middle Aged
Piperazines--therapeutic use
Prognosis
Protein Kinase Inhibitors--therapeutic use
Protein-Tyrosine Kinases--antagonists & inhibitors
Proto-Oncogene Proteins--biosynthesis
Pyrimidines--therapeutic use
Survival Rate
Young Adult
Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate. [electronic resource] - Hematology (Amsterdam, Netherlands) Aug 2009 - 220-3 p. digital
Publication Type: Journal Article
1607-8454
10.1179/102453309X426245 doi
Adaptor Proteins, Signal Transducing
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--therapeutic use
Benzamides
DNA-Binding Proteins--biosynthesis
Female
Humans
Imatinib Mesylate
LIM Domain Proteins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Male
Metalloproteins--biosynthesis
Middle Aged
Piperazines--therapeutic use
Prognosis
Protein Kinase Inhibitors--therapeutic use
Protein-Tyrosine Kinases--antagonists & inhibitors
Proto-Oncogene Proteins--biosynthesis
Pyrimidines--therapeutic use
Survival Rate
Young Adult